{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:32:55Z","timestamp":1789471975959,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,18]],"date-time":"2018-02-18T00:00:00Z","timestamp":1518912000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00417-018-3928-6","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T18:58:54Z","timestamp":1518893934000},"page":"801-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies"],"prefix":"10.1007","volume":"256","author":[{"given":"Iris","family":"Deitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radgonde","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Tomkins-Netzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohar","family":"Habot-Wilner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Friling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,18]]},"reference":[{"key":"3928_CR1","doi-asserted-by":"publisher","unstructured":"Lerman MA, Rabinovich CE (2015) The future is now: biologics for non-infectious pediatric anterior uveitis. Pediatr Drugs. \n                    https:\/\/doi.org\/10.1007\/s40272-015-0128-2","DOI":"10.1007\/s40272-015-0128-2"},{"key":"3928_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492\u2013513","journal-title":"Am J Ophthalmol"},{"key":"3928_CR3","doi-asserted-by":"publisher","unstructured":"Kahn P, Weiss M, Imundo LF, Levy DM (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2006.01.005","DOI":"10.1016\/j.ophtha.2006.01.005"},{"key":"3928_CR4","doi-asserted-by":"publisher","unstructured":"Ardoin SP, Kredich D, Rabinovich E et al (2007) Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2007.08.018","DOI":"10.1016\/j.ajo.2007.08.018"},{"key":"3928_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/bjo.2006.103721","volume":"91","author":"S Biester","year":"2007","unstructured":"Biester S, Deuter C, Michels H et al (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91:319\u2013324. \n                    https:\/\/doi.org\/10.1136\/bjo.2006.103721","journal-title":"Br J Ophthalmol"},{"key":"3928_CR6","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","volume":"119","author":"M D\u00edaz-Llopis","year":"2012","unstructured":"D\u00edaz-Llopis M, Salom D, Garcia-De-Vicu\u00f1a C et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119:1575\u20131581. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.018","journal-title":"Ophthalmology"},{"key":"3928_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW et al (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785\u2013796. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.048","journal-title":"Ophthalmology"},{"key":"3928_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509\u2013516. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057","journal-title":"Am J Ophthalmol"},{"key":"3928_CR9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","volume":"45","author":"RK Saurenmann","year":"2006","unstructured":"Saurenmann RK, Levin AV, Rose JB et al (2006) Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 45:982\u2013989. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kel030","journal-title":"Rheumatology (Oxford)"},{"key":"3928_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjo.2007.124081","volume":"91","author":"M Gallagher","year":"2007","unstructured":"Gallagher M, Quinones K, Cervantes-Casta\u00f1eda RA et al (2007) Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 91:1341\u20131344. \n                    https:\/\/doi.org\/10.1136\/bjo.2007.124081","journal-title":"Br J Ophthalmol"},{"key":"3928_CR11","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1093\/rheumatology\/ken298","volume":"47","author":"G Simonini","year":"2008","unstructured":"Simonini G, Zannin ME, Caputo R et al (2008) Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology 47:1510\u20131514. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/ken298","journal-title":"Rheumatology"},{"key":"3928_CR12","doi-asserted-by":"publisher","first-page":"264 LP","DOI":"10.1136\/annrheumdis-2016-eular.6053","volume":"75","author":"AV Ramanan","year":"2016","unstructured":"Ramanan AV, Dick AD, Jones AP et al (2016) THU0213 adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis: the sycamore trial. Ann Rheum Dis 75:264 LP\u2013264265","journal-title":"Ann Rheum Dis"},{"key":"3928_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/bjo.87.7.879","volume":"87","author":"J Boer De","year":"2003","unstructured":"De Boer J, Wulffraat N, Rothova a (2003) Visual loss in uveitis of childhood. Br J Ophthalmol 87:879\u2013884. \n                    https:\/\/doi.org\/10.1136\/bjo.87.7.879","journal-title":"Br J Ophthalmol"},{"key":"3928_CR14","doi-asserted-by":"publisher","unstructured":"Cunningham ET (2000) Uveitis in children, Ocular Immunology and Inflammation, 8(4):251-261. \n                    https:\/\/doi.org\/10.1076\/ocii.8.4.251.6459","DOI":"10.1076\/ocii.8.4.251.6459"},{"key":"3928_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaapos.2008.03.007","volume":"12","author":"K Sabri","year":"2008","unstructured":"Sabri K, Saurenmann RK, Silverman ED, Levin AV (2008) Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS 12:539\u2013545. \n                    https:\/\/doi.org\/10.1016\/j.jaapos.2008.03.007","journal-title":"J AAPOS"},{"key":"3928_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0002-9394(02)02148-7","volume":"135","author":"C Edelsten","year":"2003","unstructured":"Edelsten C, Reddy MA, Stanford MR, Graham EM (2003) Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol 135:676\u2013680. \n                    https:\/\/doi.org\/10.1016\/S0002-9394(02)02148-7","journal-title":"Am J Ophthalmol"},{"key":"3928_CR17","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/rheumatology\/kes212","volume":"51","author":"ES Sen","year":"2012","unstructured":"Sen ES, Sharma S, Hinchcliffe A et al (2012) Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease\u2014a case cohort interventional study. Rheumatology (Oxford) 51:2199\u20132203. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kes212","journal-title":"Rheumatology (Oxford)"},{"key":"3928_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10384-013-0294-0","volume":"58","author":"T Kaburaki","year":"2014","unstructured":"Kaburaki T, Namba K, Sonoda K et al (2014) Beh\u00e7et\u2019s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol 58:120\u2013130. \n                    https:\/\/doi.org\/10.1007\/s10384-013-0294-0","journal-title":"Jpn J Ophthalmol"},{"key":"3928_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00417-013-2552-8","volume":"252","author":"M Schaap-Fogler","year":"2014","unstructured":"Schaap-Fogler M, Amer R, Friling R et al (2014) Anti-TNF-\u03b1 agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol 252:633\u2013640. \n                    https:\/\/doi.org\/10.1007\/s00417-013-2552-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3928_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","volume":"113","author":"RT Rajaraman","year":"2006","unstructured":"Rajaraman RT, Kimura Y, Li S et al (2006) Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113:308\u2013314. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2005.09.037","journal-title":"Ophthalmology"},{"key":"3928_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","volume":"34","author":"PJ Anderson","year":"2005","unstructured":"Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34:19\u201322. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2005.01.005","journal-title":"Semin Arthritis Rheum"},{"key":"3928_CR22","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096\u20133106. \n                    https:\/\/doi.org\/10.1002\/art.22838","journal-title":"Arthritis Rheum"},{"key":"3928_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbink","year":"2006","unstructured":"Wolbink GJ, Vis M, Lems W et al (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54:711\u2013715. \n                    https:\/\/doi.org\/10.1002\/art.21671","journal-title":"Arthritis Rheum"},{"key":"3928_CR24","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0161-6420(01)00576-0","volume":"108","author":"CM Samson","year":"2001","unstructured":"Samson CM, Waheed N, Baltatzis S, Foster CS (2001) Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108:1134\u20131139","journal-title":"Ophthalmology"},{"key":"3928_CR25","doi-asserted-by":"publisher","unstructured":"Lerman MA, Burnham JM, Chang PY et al (2013) Response of pediatric uveitis to tumor necrosis factor-\u03b1 inhibitors. J Rheumatol. \n                    https:\/\/doi.org\/10.3899\/jrheum.121180","DOI":"10.3899\/jrheum.121180"},{"key":"3928_CR26","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00417-015-3124-x","volume":"253","author":"R Sella","year":"2015","unstructured":"Sella R, Oray M, Friling R et al (2015) Dexamethasone intravitreal implant (Ozurdex\u00ae) for pediatric uveitis. Graefes Arch Clin Exp Ophthalmol 253:1777\u20131782. \n                    https:\/\/doi.org\/10.1007\/s00417-015-3124-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3928_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3899\/jrheum.120583","volume":"40","author":"ME Zannin","year":"2013","unstructured":"Zannin ME, Birolo C, Gerloni VM et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry. J Rheumatol 40:74\u201379. \n                    https:\/\/doi.org\/10.3899\/jrheum.120583","journal-title":"J Rheumatol"},{"key":"3928_CR28","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/acr.20404","volume":"63","author":"G Simonini","year":"2011","unstructured":"Simonini G, Taddio A, Cattalini M et al (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 63:612\u2013618. \n                    https:\/\/doi.org\/10.1002\/acr.20404","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3928_CR29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/archopht.125.7.895","volume":"125","author":"L Sobrin","year":"2007","unstructured":"Sobrin L, Kim EC, Christen W et al (2007) Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 125:895","journal-title":"Arch Ophthalmol"},{"key":"3928_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/14740338.2015.1042453","volume":"14","author":"G Horneff","year":"2015","unstructured":"Horneff G (2015) Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf 14:1111\u20131126. \n                    https:\/\/doi.org\/10.1517\/14740338.2015.1042453","journal-title":"Expert Opin Drug Saf"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-018-3928-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-3928-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-3928-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T19:04:15Z","timestamp":1550430255000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-018-3928-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,18]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["3928"],"URL":"https:\/\/doi.org\/10.1007\/s00417-018-3928-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,18]]},"assertion":[{"value":"9 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Michal Kramer served as an advisor to Abbvie and as principal investigator in a clinical trial, not related to this study. All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}